SALT LAKE CITY--(BUSINESS WIRE)--Freshmedx today announced that its ground-breaking study on the use of computed bioconductance technology in detecting lung cancer will be published in the April edition of the Journal of Thoracic Oncology. Freshmedx’s proprietary CB Test is a non-invasive adjunctive test that can evaluate patients with lesions suspicious for lung cancer, and evaluate the likelihood that indeterminate lung lesions are malignant or benign.
